Biomeasures and mechanistic modeling highlight PK/PD risks for a monoclonal antibody targeting Fn14 in kidney disease

References

• Kamath AV. Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies. Drug discovery today Technologies 2016; 21–22:75–83.
   PubMedGoogle Scholar
• Brodfuehrer J, Rankin A, Edmonds J, Keegan S, Andreyeva T, Lawrence-Henderson R, et al. Quantitative analysis of target coverage and germinal center response by a CXCL13 neutralizing antibody in a T-dependent mouse immunization model. Pharmaceutical research 2014; 31:635–48.
   PubMed Web of Science ®Google Scholar
• Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V, et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 2001; 15:837–46.
   PubMed Web of Science ®Google Scholar
• Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nature reviews Drug discovery 2008;7:411–25.
   PubMed Web of Science ®Google Scholar
• Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, et al. Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. Journal of immunology 2003;170:341–8.
   PubMed Web of Science ®Google Scholar
• Cheng E, Armstrong CL, Galisteo R, Winkles JA. TWEAK/Fn14 Axis-Targeted Therapeutics: Moving Basic Science Discoveries to the Clinic. Frontiers in immunology 2013;4:473.
   PubMed Web of Science ®Google Scholar
• Roos C, Wicovsky A, Muller N, Salzmann S, Rosenthal T, Kalthoff H, et al. Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway. Journal of immunology 2010;185:1593–605.
   PubMed Web of Science ®Google Scholar
• Salzmann S, Seher A, Trebing J, Weisenberger D, Rosenthal A, Siegmund D, et al. Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity. The Journal of biological chemistry 2013;288:13455–66.
   PubMed Web of Science ®Google Scholar
• Brown SA, Hanscom HN, Vu H, Brew SA, Winkles JA. TWEAK binding to the Fn14 cysteine-rich domain depends on charged residues located in both the A1 and D2 modules. The Biochemical journal 2006;397:297–304.
   PubMed Web of Science ®Google Scholar
• Brown SA, Richards CM, Hanscom HN, Feng SL, Winkles JA. The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation. The Biochemical journal 2003;371:395–403.
   PubMed Web of Science ®Google Scholar
• Han S, Yoon K, Lee K, Kim K, Jang H, Lee NK, et al. TNF-related weak inducer of apoptosis receptor, a TNF receptor superfamily member, activates NF-kappa B through TNF receptor-associated factors. Biochemical and biophysical research communications 2003;305:789–96.
   PubMed Web of Science ®Google Scholar
• Sharif MN, Campanholle G, Nagiec EE, Wang J, Syed J, O'Neil SP, et al. Soluble Fn14 Is Detected and Elevated in Mouse and Human Kidney Disease. PloS one 2016;11:e0155368.
   PubMed Web of Science ®Google Scholar
• Meighan-Mantha RL, Hsu DK, Guo Y, Brown SA, Feng SL, Peifley KA, et al. The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. The Journal of biological chemistry 1999;274:33166–76.
   PubMed Web of Science ®Google Scholar
• Feng SL, Guo Y, Factor VM, Thorgeirsson SS, Bell DW, Testa JR, et al. The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. The American journal of pathology 2000;156:1253–61.
   PubMed Web of Science ®Google Scholar
• Justo P, Sanz AB, Sanchez-Nino MD, Winkles JA, Lorz C, Egido J, et al. Cytokine cooperation in renal tubular cell injury: the role of TWEAK. Kidney international 2006;70:1750–8.
   PubMed Web of Science ®Google Scholar
• Weinberg JM. TWEAK-Fn14 as a mediator of acute kidney injury. Kidney international 2011;79:151–3.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Burkly LC, Campbell S, Schwartz N, Molano A, Choudhury A, et al. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. Journal of immunology 2007;179:7949–58.
   PubMed Web of Science ®Google Scholar
• Molano A, Lakhani P, Aran A, Burkly LC, Michaelson JS, Putterman C. TWEAK stimulation of kidney resident cells in the pathogenesis of graft versus host induced lupus nephritis. Immunology letters 2009;125:119–28.
   PubMed Web of Science ®Google Scholar
• Sanz AB, Sanchez-Nino MD, Izquierdo MC, Jakubowski A, Justo P, Blanco-Colio LM, et al. Tweak induces proliferation in renal tubular epithelium: a role in uninephrectomy induced renal hyperplasia. Journal of cellular and molecular medicine 2009;13:3329–42.
   PubMed Web of Science ®Google Scholar
• Sanz AB, Sanchez-Nino MD, Ortiz A. TWEAK, a multifunctional cytokine in kidney injury. Kidney international 2011;80:708–18.
   PubMed Web of Science ®Google Scholar
• Xia Y, Campbell SR, Broder A, Herlitz L, Abadi M, Wu P, et al. Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis. Clinical immunology 2012;145:108–21.
   PubMed Web of Science ®Google Scholar
• Sanchez-Nino MD, Poveda J, Sanz AB, Mezzano S, Carrasco S, Fernandez-Fernandez B, et al. Fn14 in podocytes and proteinuric kidney disease. Biochimica et biophysica acta 2013;1832:2232–43.
   PubMed Web of Science ®Google Scholar
• Sanz AB, Izquierdo MC, Sanchez-Nino MD, Ucero AC, Egido J, Ruiz-Ortega M, et al. TWEAK and the progression of renal disease: clinical translation. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association – European Renal Association 2014;29:Suppl 1:i54–i62.
   PubMed Web of Science ®Google Scholar
• Michaelson JS, Wisniacki N, Burkly LC, Putterman C. Role of TWEAK in lupus nephritis: a bench-to-bedside review. Journal of autoimmunity 2012;39:130–42.
   PubMed Web of Science ®Google Scholar
• Sanz AB, Justo P, Sanchez-Nino MD, Blanco-Colio LM, Winkles JA, Kreztler M, et al. The cytokine TWEAK modulates renal tubulointerstitial inflammation. Journal of the American Society of Nephrology: JASN 2008;19:695–703.
   PubMed Web of Science ®Google Scholar
• Xia Y, Herlitz LC, Gindea S, Wen J, Pawar RD, Misharin A, et al. Deficiency of fibroblast growth factor-inducible 14 (Fn14) preserves the filtration barrier and ameliorates lupus nephritis. Journal of the American Society of Nephrology: JASN 2015;26:1053–70.
   PubMed Web of Science ®Google Scholar
• Tajrishi MM, Zheng TS, Burkly LC, Kumar A. The TWEAK-Fn14 pathway: a potent regulator of skeletal muscle biology in health and disease. Cytokine & growth factor reviews 2014;25:215–25.
   PubMed Web of Science ®Google Scholar
• Novoyatleva T, Sajjad A, Engel FB. TWEAK-Fn14 Cytokine-Receptor Axis: A New Player of Myocardial Remodeling and Cardiac Failure. Frontiers in immunology 2014;5:50.
   PubMed Web of Science ®Google Scholar
• Yepes M. TWEAK and the central nervous system. Molecular neurobiology 2007;35:255–65.
   PubMed Web of Science ®Google Scholar
• Tirnitz-Parker JE, Viebahn CS, Jakubowski A, Klopcic BR, Olynyk JK, Yeoh GC, et al. Tumor necrosis factor-like weak inducer of apoptosis is a mitogen for liver progenitor cells. Hepatology 2010;52:291–302.
   PubMed Web of Science ®Google Scholar
• Yoriki R, Akashi S, Sho M, Nomi T, Yamato I, Hotta K, et al. Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Experimental and therapeutic medicine 2011;2:103–8.
   PubMed Web of Science ®Google Scholar
• Son A, Oshio T, Kawamura YI, Hagiwara T, Yamazaki M, Inagaki-Ohara K, et al. TWEAK/Fn14 pathway promotes a T helper 2-type chronic colitis with fibrosis in mice. Mucosal immunology 2013;6:1131–42.
   PubMed Web of Science ®Google Scholar
• Karaca G, Xie G, Moylan C, Swiderska-Syn M, Guy CD, Kruger L, et al. Role of Fn14 in acute alcoholic steatohepatitis in mice. American journal of physiology Gastrointestinal and liver physiology 2015;308:G325–34.
   PubMed Web of Science ®Google Scholar
• Wen J, Doerner J, Weidenheim K, Xia Y, Stock A, Michaelson JS, et al. TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice. Journal of autoimmunity 2015;60:40–50.
   PubMed Web of Science ®Google Scholar
• Ren MY, Sui SJ. The role of TWEAK/Fn14 in cardiac remodeling. Molecular biology reports 2012;39:9971–7.
   PubMed Web of Science ®Google Scholar
• Novoyatleva T, Janssen W, Wietelmann A, Schermuly RT, Engel FB. TWEAK/Fn14 axis is a positive regulator of cardiac hypertrophy. Cytokine 2013;64:43–5.
   PubMed Web of Science ®Google Scholar
• Poveda J, Tabara LC, Fernandez-Fernandez B, Martin-Cleary C, Sanz AB, Selgas R, et al. TWEAK/Fn14 and Non-Canonical NF-kappaB Signaling in Kidney Disease. Frontiers in immunology 2013;4:447.
   PubMed Web of Science ®Google Scholar
• Zheng TS, Burkly LC. No end in site: TWEAK/Fn14 activation and autoimmunity associated- end-organ pathologies. Journal of leukocyte biology 2008;84:338–47.
   PubMed Web of Science ®Google Scholar
• Izumi Y, Yabe D, Taniguchi A, Fukushima M, Nakai Y, Hosokawa M, et al. Circulating TNF receptor 2 is associated with the development of chronic kidney disease in non-obese Japanese patients with type 2 diabetes. Diabetes research and clinical practice 2013;99:145–50.
   PubMed Web of Science ®Google Scholar
• Galluppi GR, Wisniacki N, Stebbins C. Population pharmacokinetic and pharmacodynamic analysis of BIIB023, an anti-TNF-like weak inducer of apoptosis (anti-TWEAK) monoclonal antibody. British journal of clinical pharmacology 2016;82:118–28.
   PubMed Web of Science ®Google Scholar
• Li L, Gardner I, Rose R, Jamei M. Incorporating Target Shedding Into a Minimal PBPK-TMDD Model for Monoclonal Antibodies. CPT: pharmacometrics & systems pharmacology 2014;3:e96.
   PubMedGoogle Scholar
• Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer chemotherapy and pharmacology 2005;56:361–9.
   PubMed Web of Science ®Google Scholar
• Glassman PM, Balthasar JP. Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. Cancer biology & medicine 2014;11:20–33.
   PubMedGoogle Scholar
• Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nature medicine 2006;12:856–61.
   PubMed Web of Science ®Google Scholar
• Knauf MJ, Bell DP, Hirtzer P, Luo ZP, Young JD, Katre NV. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. The Journal of biological chemistry 1988;263:15064–70.
   PubMed Web of Science ®Google Scholar
• Wartiovaara J, Ofverstedt LG, Khoshnoodi J, Zhang J, Makela E, Sandin S, et al. Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography. The Journal of clinical investigation 2004;114:1475–83.
   PubMed Web of Science ®Google Scholar
• Tabrizi MA, Bornstein GG, Klakamp SL. Development of antibody-based therapeutics: translational considerations. Springer Science & Business Media, 2012.
   Google Scholar
• Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. Journal of pharmacokinetics and pharmacodynamics 2012;39:67–86.
   PubMed Web of Science ®Google Scholar
• Tiwari A, Luo H, Chen X, Singh P, Bhattacharya I, Jasper P, et al. Assessing the Impact of Tissue Target Concentration Data on Uncertainty in In Vivo Target Coverage Predictions. CPT: pharmacometrics & systems pharmacology 2016;5:565–74.
   PubMedGoogle Scholar
• Kuang B, King L, Wang HF. Therapeutic monoclonal antibody concentration monitoring: free or total? Bioanalysis 2010;2:1125–40.
   PubMed Web of Science ®Google Scholar
• Price JC, Holmes WE, Li KW, Floreani NA, Neese RA, Turner SM, et al. Measurement of human plasma proteome dynamics with (2)H(2)O and liquid chromatography tandem mass spectrometry. Analytical biochemistry 2012;420:73–83.
   PubMed Web of Science ®Google Scholar
• Foster DM, Barrett PH, Toffolo G, Beltz WF, Cobelli C. Estimating the fractional synthetic rate of plasma apolipoproteins and lipids from stable isotope data. Journal of lipid research 1993;34:2193–205.
   PubMed Web of Science ®Google Scholar